153 related articles for article (PubMed ID: 26369526)
1. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Thibault G; Paintaud G; Legendre C; Merville P; Coulon M; Chasseuil E; Ternant D; Rostaing L; Durrbach A; Di Giambattista F; Büchler M; Lebranchu Y
Transpl Int; 2016 Feb; 29(2):184-95. PubMed ID: 26369526
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
3. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
5. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
[TBL] [Abstract][Full Text] [Related]
7. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication.
Höcker B; Kovarik JM; Daniel V; Opelz G; Fehrenbach H; Holder M; Hoppe B; Hoyer P; Jungraithmayr TC; Köpf-Shakib S; Laube GF; Müller-Wiefel DE; Offner G; Plank C; Schröder M; Weber LT; Zimmerhackl LB; Tönshoff B
Transplantation; 2008 Nov; 86(9):1234-40. PubMed ID: 19005405
[TBL] [Abstract][Full Text] [Related]
10. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
[TBL] [Abstract][Full Text] [Related]
11. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
12. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
14. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.
Krystufkova E; Sekerkova A; Striz I; Brabcova I; Girmanova E; Viklicky O
Nephrol Dial Transplant; 2012 Jun; 27(6):2576-82. PubMed ID: 22167587
[TBL] [Abstract][Full Text] [Related]
16. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients.
Kovarik JM; Pescovitz MD; Sollinger HW; Kaplan B; Legendre C; Salmela K; Book BK; Gerbeau C; Girault D; Somberg K;
Clin Transplant; 2001 Apr; 15(2):123-30. PubMed ID: 11264639
[TBL] [Abstract][Full Text] [Related]
17. [Regulatory T cells in kidney transplant recipients].
Libetta C; Portalupi V; Margiotta E; Sepe V; Canevari M; Meloni F; Morosini M; Dal Canton A
G Ital Nefrol; 2009; 26 Suppl 45():S54-7. PubMed ID: 19382095
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
Brakemeier S; Arns W; Lehner F; Witzke O; Vonend O; Sommerer C; Mühlfeld A; Rath T; Schuhmann R; Zukunft B; Kroeger I; Porstner M; Budde K
PLoS One; 2019; 14(9):e0222730. PubMed ID: 31536556
[TBL] [Abstract][Full Text] [Related]
20. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
